Activated microglia: The silent executioner in neurodegenerative disease? Stanley H. AppelEricka P. Simpson Invited Commentary Pages: 303 - 305
Parkinson’s disease: The treatment of drug-induced hallucinations and psychosis Eric S. MolhoStewart A. Factor OriginalPaper Pages: 320 - 328
Initial treatment of early Parkinson’s disease: A review of recent, randomized controlled trials Kevin BiglanRobert G. Holloway ReviewPaper Pages: 329 - 336
Focal dystonia: The role of botulinum toxin Ron TintnerJoseph Jankovic OriginalPaper Pages: 337 - 345
Measurement of quality of life in neurodegenerative disorders Mickie D. Welsh OriginalPaper Pages: 346 - 349
Advances in neuroimaging: Non-substrate-directed partial epilepsy Simona TigaranTerence J. O’BrienGregory D. Cascino OriginalPaper Pages: 361 - 368
Etiology, diagnosis, and treatment of nonepileptic seizures John J. BarryKatherine Sanborn OriginalPaper Pages: 381 - 389
Advances in our understanding of early childhood epilepsies: 1999–2000 Douglas R. Nordli Jr.Elaine WyllieKatherine D. Holland OriginalPaper Pages: 390 - 395